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Summary Studies were initiated to assess the response of patients with disseminated melanoma to
recombinant a interferon (rIFN-aA) and to monitor effects of rIFN-aA on several tests of immune function.
Twenty patients were treated with rIFN-aA given by i.m. injection in escalating doses from 15 to
50 x 106 u m2. The responses of two patients were considered unevaluable. Of the remainder there was
complete remission of tumour in two and stable disease in two. Subsequent progression of tumour in one of
the latter patients coincided with development of antibodies to IFN. Side effects (usually fatigue) were dose
rate limiting in 11 patients.
Laboratory tests on samples taken 6 hours after rIFN-aA indicated a marked lymphopenia and a reduction
in natural killer (NK) cell activity particularly against K562 target cells. Longer term changes measured in
samples taken 2 days after the previous rIFN-aA injections consisted of neutropenia and an increase in the
T4/T8 ratio due mainly to a relative increase in OKT4 positive T cells compared to OKT8 positive T cells.
NK activity against the K562 target cell increased in most patients during the first week of treatment and then
returned to below or near pretreatment levels thereafter against the K562 target cell. This contrasted with NK
activity against the melanoma target cell which showed a more gradual increase over the duration of the
treatment in 6 patients. The latter correlated with an increase in mitogen stimulated IL 2 production from
their blood lymphocytes and may indicate that the cytotoxic activity resulted from lymphokine-activated killer
(LAK) cells.
These results confirm the activity of rIFN-aA against melanoma in certain patients. They suggest that
further studies are needed to select patients who may respond to rIFN-aA and to optimize treatment
regimens. Tests of IL 2 production and LAK activity may assisted in achieving these objectives.
Systemic therapy for patients with unresectable
metastatic melanoma is extremely poor and a
variety of reignens have not altered the median
survivals of the disease (Amer et al., 1979; Feun
et al., 1982). Recent Phase I and II studies with
leukocyte interferon (IFN-a) suggested that IFN-a
from whole cells had activity against melanomas in
a small proportion of patients (Krown et al.,
1981). Similar limited responses were also seen in
patients treated with lymphoblastoid IFN (Retsas
et al., 1983). The amount of IFN from these sources
was limited and it has only been with the advent
of recombinant DNA technology that sufficient
quantities of purified IFNs have been available for
clinical studies over a wide range of dosages and
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different schedules. Two recombinant IFN-as have
received preliminary evaluation in patients with
cancer, rIFN-aA distributed by Hoffman-LaRoche
and rIFN-a2 from the Schering-Plough Corporation.
rIFN-aA given in similar doses to leukocyte IFN
was shown to produce equivalent levels of
antiviral activity and to have a similar effects
(Gutterman et al., 1982).
In studies on patients with a variety of
malignancies, objective responses were mainly seen
in patients with lymphoma (Quesada & Gutterman,
1983). Evaluation of these products in patients with
melanoma is as yet, at an early stage. In a
preliminary study IFN-a2 was given i.v. to 16
patients with disseminated melanoma using various
dose regimes. Two patients had complete remissions
and 5 had stabilization of their disease (Ernstoff et
al., 1983). Similar response rates were reported for
rIFN-aA (Creagan, 1983, 1984a,b).
The purpose of the present study was to further
evaluate the therapeutic efficacy of rIFN-aA given
in high doses i.m. in patients with metastatic
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melanoma and to monitor a variety of immune
responses to determine whether these may assist in
optimizing treatment in subsequent studies.
Materials and methods
Patients studied
These were 15 patients attending the Sydney
Melanoma Unit and 5 patients attending the
Newcastle Melanoma Unit, with metastases from
melanoma. A summary of their clinical details is
given in Table I. Twelve were in good physical
condition with a performance status of 0-1 assessed
on a 5 point scale (Miller et al., 1981) whereas 8
had restriction on activities due to their disease.
Eleven had no previous treatment and two had
received vaccinations with a melanoma cell vaccinia
lysate. Only 5 patients (2, 3, 13, 16 and 19) had
chemotherapy and/or radiotherapy within the
preceding 6 months.
IFN administration and study design
rIFN-oaA (RO 22-8181) was supplied by Roche
products (Dee Why, N.S.W.) as a freeze dried
preparation in ampoules of 3, 18 and
50 x 106uml-1 (Muml-1). The preparation was
reconstituted immediately before use and given by
i.m. injection in the gluteal region 3 times a week
on a Monday, Wednesday and Friday.
All patients had thorough clinical examinations
and careful staging of their disease including
computerized tomography (when appropriate)
before initiation of rIFN-axA treatment. Complete
blood cell counts, differential count and platelet
counts, blood chemistry, urinalysis, electrocardio-
gram and chest X-ray were performed prior to
commencement of treatment. Patients were
admitted to hospital for initiation of treatment and
rIFN-ai given in escalating doses of 15 and
30Mu m-2 on two separate occasions and then
50Mum-2 thereafter.
Vital signs were recorded before each injection
and hourly for 4-6h post injection. All patients
were followed up by physical examination at two
weekly intervals. Peripheral blood cell counts were
repeated prior to each injection, in the first week
then each week for 6 weeks and each 2 weeks
thereafter. Blood chemistry was repeated once a
week for 6 weeks then each 4 weeks. Chest X-ray
and urinalysis was repeated each 4 weeks. Tumour
status was reassessed at least once a month by tests
pertinent to each patient. Treatment was dis-
continued if severe toxicity (Miller et al., 1981)
and/or tumour progression became apparent.
Criteria ofresponse
Following the recommendations of Miller et al.
(1981), complete response was defined as the
disappearance of all clinical evidence of active
tumour for a minimum of 4 weeks. Partial response
was defined as a 50% or greater decrease in the
products of the perpendicular diameters of
measurable lesions with no progression of any
existing lesions or the development of new lesions.
Stable disease was defined as no response and
<25% increase in the size of lesions and the
absence of new lesions. Progressive disease was
defined as an increase of >25% in the size of the
measurable lesions or the appearance of new
lesions.
Immunological tests
Estimation of lymphocytes subpopulations in blood
Mononuclear cells were separated from defibrinated
blood samples by centrifugation on hypaque-
ficoll using standard techniques. T cell populations
were defined by use of monoclonal antibodies
OKT3, OKT4 and OKT8 (Ortho Diagnostics,
North Ryde, N.S.W.) and peroxidase labelled rabbit
anti-mouse immunoglobulin (Dako Patts, Code,
P. 161).
Cells (3-5 x 105) in 30,l were placed on a slide,
air dried and fixed in acetone for 5 min. They were
washed in PBS, incubated with 0.03% H202 for
5min and washed with PBS+ 1%BSA. Twenty
microlitres of a 1 in 4 dilution of the monoclonal
antibody was added for 30min at room
temperature and after washing the cells were
incubated in a 1:20 dilution of the second antibody.
They were washed and the incubated with the
substrate, 3-amino-9-ethyl-ethylcarbazole, prepared
as described elsewhere, (Hersey et al., 1983) for
15min, stained with haematoxylin and mounted in
Glycergel (Dako) for examination by bright field
microscopy.
Measurement ofNK activity
The methods used to measure NK activity against
the MM200 and K562 myeloid cells in 51Cr release
assays are described elsewhere (Hersey et al., 1980,
1981). Blood monoculear cells (3 x 105, 105, and
3 x IO' in 0.5ml) were incubated with 3 x I03 51Cr-
labelled MM200 or 104 K562 cells (in 0.5ml) in
overnight 16h assays in duplicate round bottomed
tubes. Supernatants (0.5ml) were harvested after
centrifugation at 5OOg 7min and counted.
Percentage of 51Cr release was calculated by the
formula 2a/a+b x 100, where a=counts in
supernatant alone tube minus machine background
and b=counts in tube with target cells and half the
supernatant. Percent specific cytotoxicity wasEFFECTS OF rIFN-acA IN MELANOMA PATIENTS 817
calculated as follows: Results
%51Cr release test-
°0 spontaneous 5"Cr release
Maximum % 51Cr release- 100
% spontaneous 51Cr release
Lytic units were defined as the number of effector
cells required to lyse 20% of the target cells and
were expressed per 106 of the lymphocyte
population [LU(20%0/106)] (Pross & Baines, 1982).
These values were compared to the mean value of
two frozen thawed controls carried out in parallel
with the test subjects. If the value of the controls
was outside the mean+2 s.e. of the mean control
value (estimated form .20 tests), the test value was
multiplied by a multiple obtained by dividing the
control value on that day by the mean control
value.
Measurement ofIL2 production and assay ofIL2
Blood lymphocytes, 4 x 106 in 2ml of RPMI (no
FCS), were incubated with 1% PHA (Wellcome
Pharmaceuticals, Code HA15) for 36h in flat
bottomed Bijou bottles. The supernatants were
collected and assayed at 4 dilutions for mitogenic
activity against the NK-7, IL 2 dependent, murine
cell line (111-E3) kindly provided by Professor
Kumagai and described elsewhere (Suzuki et al.,,
1983). In brief, supernatant (100lul) was added in
doubling dilutions to triplicate cells with
2xl04 NK-7 cells for 18h and pulsed with lCi
125IUDR for 6h. A unit of IL2 was defined as the
reciprocal dilution that induced 50% of the
maximum IUDR uptake of a standard IL 2
preparation included in each assay. To reduce
variability, supernatants from IL 2 production
assays as above from each patient, were stored until
the treatment with interferom was complete and all
supernatants assayed at once against the NK-7
cells.
Statistical analysis
The complete remission rate and 95% confidence
limits were obtained from the binomial distribution
tables. Sequential changes in leukocyte populations
were tested for significance by analysis of one way
variance using data collected on days 1, 3, 10 and
31 using the "minitab" statistical package. Median
survival was estimated from life tables constructed
as described by Kaplan & Meier (1958). Analysis of
the significance of short term changes in NK
activity during treatment with rIFN-ocA was carried
out by paired t test.
Effect ofrIFN-aA on tumour growth
With the exception of patients 2 and 10 all patients
were considered evaluable. Patient 2 had extensive
tumour growth in the cervical region and
discomfort from this was increased by the side
effects associated with rIFN-cxA, leading to
cessation of treatment before response could be
assessed. Patient 10 had metastatic disease in the
neck of the L femur which had been monitored by
serial X-rays. After 4 weeks there was an increase
in the lytic area seen on X-ray and this was taken
as evidence of progression. At operation for
insertion of a pin and plate a month later, however,
there was no evidence of tumour in tissue removed
from the neck of the femur. Residual foci of
melanoma cells could not be excluded by this
procedure but there was no clinical evidence of
recurrent tumour growth at this site to the time of
death 1 year later. (Recurrent spinal metastases
were detected 5 months after treatment with rIFN-
aA.)
Two patients appeared to have complete
remission of tumour growth. Patient 4 had a 1 cm2
nodule in the left lower lung field which resolved
completely after 4 weeks of treatment. He reamined
well for one year at which time a further s.c.
recurrence was detected near the site of his primary.
There was no clinical evidence of systemic disease
at this time. Patient 20 had 6s.c. metastases and 4
pulmonary metastases involving both lung fields.
These resolved after 10 weeks of treatment. No
response was seen in the first 4 weeks of therapy.
Patient 8 had extensive liver metastases which was
monitored by serial CAT scans and biochemistry.
There was no change in the size of the lesions by
CAT scans but biochemistry returned towards
normal over the 8 month treatment period. On
cessation of rIFN-aA there was rapid progression of
lesions in the liver by CAT scans and clinical
examination and worsening of liver biochemistry.
Patient 9 had shown progression of s.c. and
pulmonary lesions until commencement of rIFN-aA.
These remained stable or decreased slightly in size
on treatment for 9 weeks at which time new s.c.
nodules and increased size of existing nodules were
noted. These events coincided with detection of
antibodies to rIFN-oA by radioimmunoassay.
Ten patients had evidence of disease progression
within 5 weeks of commencing rIFN-aA treatment
and these were patients with poor performance
status before initiation of treatment.
Effects ofrIFN-axA on blood leukocyte populations
Changes in blood leukocyte populations in samples
taken from 15 patients treated at the Sydney818 P. HERSEY et al.
Table I Clinical details of patients entered into study of response to rIFN-aA
Months
Perfor- to Duration Duration
mance detection rIFN-aAa of of SurvivaP
Patient status Primary Site of of started Previous treatment response (weeks)
no. (ECOG) Sex Age site metastases metastases (months) treatment (weeks) Outcome (weeks) (4/1/85)
1 1 M 41 Trunk Lung
Sacum
2 2 M 42 Head Cx LN sc
Lung
3 2 F 61 Leg Ing LN sc
Abd. LN
4 0 M 68 Leg Lung
5 1 F 44 Trunk Sternum
sc Trunk
6 1 M 48 Trunk sc Trunk
Lung
7 2 F 42 Leg Bowel
sc Trunk
8 0 F 30 Head Liver
9 0 M 53 Trunk sc Head
Ax LN
Lung
10 2 M 23 Trunk Spine, neck
of femur
11 1 M 27 Trunk sc Trunk
12 2 M 29 Trunk sc Bowel &
Lung
13 1 F 43 Leg Bowel
Lung
14 2 F 36 Trunk sc Trunk
As LN
Bowel,
Liver
15 1 F 35 Head Lung
16 1 M 60 Back sc Trunk
Lung
17 2 F 42 Back Adominal
(ascites)
Lung
18 2 F 44 Leg Abdominal
LN
(ascites)
Lung
19 0 M 23 Occult sc Head &
Neck
Lung
20 0 M 73 Head sc Trunk
Lung
9 13 Nil 11 PD
6 9 Bisantrene
DTIC of
Radiotherapy
11 12 DTIC
48
26
49
30
Nil
Nil
5 7 Imm
2 NEb
6 PD
8
S
CR
PD
5 PD
73 75 Nil 5 PD
34 35 DTIC
(1980)
15 17 Imm
8 17 DTIC &
Radiotherapy
43 47 Nil
93 95 Nil
13
11
96
101
104
26
6
23
52 84A
30
6
6
20 Stableb 32 88
10 Stable' 9 35
4 NEb
8
5
PD
PD
14 DTIC 8 PD
50
46
24
- 43
106 Nil 4 PD
18 19 Nil
39 51 DTIC
& BCG
Cyclophos.
96 98 Nil
8 PD 14
4 PD - 30
4 PD 4
353 355 Nil 5 PD 8
4 7 DTIC
& BCG
8 PD - 22A
8 10 Nil 20 CR 28 28A
35
A =Alive, PD =Progressive Disease, NE =Not Evaluable, CR=Complete Response, Cx=Cervical, Ax=Axilla, Ing=
Inguinal, sc=Subcutaneous, LN=Lymph nodes, Imm =Immunotherapy with vaccinia cell lysates, DTIC =Chemotherapy
with dacarbazine.
aMonths from diagnosis.
bSee text.
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Melanoma Unit 6h after administration of rIFN-
axA are summarized in Table II. The total leukocyte
count at 6h post injection was unchanged at the 15
and 30Mum-2 dose but there was a marked
reduction in lymphocyte counts and a
corresponding increase in neutrophils. The
reduction in lymphocyte count was attributed to a
loss of T cells from the circulation which affected
both T4 and T8 subpopulations. At the 50Mum-2
dose there was a reduction in both neutrophils and
lymphocytes. (There was a reciprocal increase in B
cells at all dose levels.)
In contrast to the short term effects, longer term
changes measured in blood samples taken prior to
each administration of rIFN-aA, consisted of a
reduction in total leukocyte counts which was due
mainly to a reduction in neutrophils. Lymphocyte
numbers were not markedly reduced and except for
patients 3 did not exceed 50% of the pretreatment
values. These results are shown in a summarized
form in Table III as mean values before and during
treatment. Analysis of T cell subsets by monoclonal
antibodies revealed that the reduction of the OKT8
population tended to be greater than the T4
population giving an increase in the T4/T8 ratio in
10 of the patients. Exceptions to this were results
from studies on patients 4, 6, 8, 12 and 15. These
results are summarized in Figure 1 which indicates
the change in mean lymphocyte counts whole on
treatment in relation to changes in the T4/T8 ratio.
The increase in T4/T8 ratio could not be accounted
for by changes in lymphocyte counts. There was a
significant decrease overall in B cell and monocyte
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Figure 1 Changes in mean T4/T8 ratio in relation to
changes in mean lympocyte numbers during treatment
with rIFN-aoA. Changes in lymphocyte numbers were
small and did not appear responsible for the increase
in the T4/T8 ratio seen in most patients (10/15).
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Figure 2 Sequential changes in NK activity against the K562 target cell. (a) Patients showing an increase in
the first week of treatment and (b) those showing a decrease or no change. Mean value+2 s.e. of the frozen-
thawed concurrent control PBL against the K562 target cells was 20.3+4.2 LU/20%/106 (26 estimations).
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Figure 3 Sequential changes in NK activity against
the MM200 target cell showing the different pattern of
activity to that seen against the K562 target cell.
Increased NK activity was seen in most of the patients
and this tended to be gradual and prolonged
compared to that against the K562 target cells. Mean
value+2 s.e. of the frozen thawed concurrent control
PBL against the MM200 target cells was
9.8+3.lLU/20%/106 (26 estimations). S refers to date
of cessation of rIFN-aA treatment.
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Table III Long term effects on blood leukocytes measured in blood samples taken prior to administration of rIFNaAa
Total
Wbc Lymphocytes T3 T4 T8 T4/T8 B cells Mono Platelets
Pretreatment 7.3+ 1.2 1.4+0.6 1.0+0.45 0.6+0.3 0.35+0.2 1.9+0.8 0.30+0.17 0.38+0.2 326+82
Day 3 5.2+1.4 1.5+0.6 1.1+0.4 0.7+0.2 0.37+0.2 2.1+0.7 0.33+0.20 0.36+0.16 277+75
Day 10 3.8+1.1 1.2+0.4 0.8+0.3 0.5+0.2 0.27+0.1 2.2+0.9 0.27+0.09 0.22+0.1 247+55
Day 30 3.6+1.0 1.0+0.4 0.7+0.4 0.4+0.3 0.21+0.1 2.0+0.7 0.14+0.7 0.21+0.1 222+63
F value 23.4 2.15 1.99 2.12 1.93 0.27 3.76 3.3 4.58
P <0.01 NS NS NS NS NS <0.05 <0.05 <0.01
aValues indicated are mean counts+s.d. (x 10-1-1). T4/T8 is the ratio of these 2 counts.
Table IV Short term (6h) effects of rIFN-acA on NK activitya
K562 MM200
rIFN-aA
amb pm PC am pm P
15(n=10) 30.7+11 6 +4.6 <0.001 16.4+16.5 20.2+34 NS
30(n=7) 85+72 19+13 <0.05 21.3+14 25.5+19.7 NS
50(n=8) 44.6+35.8 18.8+15.7 >0.10 23+17.8 24.5+25 NS
aLU/20%/106 lymphocytes mean+s.d.
bam and pm refer to values before and 6h after rIFN-aA administration.
CP values determined by paired t test (t was 6.47, 2.46 and 1.72 respectively).
numbers. Platelet counts showed a decrease in all
patients (except patient 2) and returned to
pretreatment values on cessation of rIFN-acA.
Changes in NK activity after rIFN-oaA administration
NK activity in lytic units against the K562 and
MM200 target cells. in blood samples taken before
and 6h after i.m. injection of IFN is summarized in
Table IV. NK activity against the K562 target cells
was markedly reduced in all instances. This was
particularly evident at the lower doses of rIFN-aA.
In contrast changes in the NK activity at 6h post
injection against the MM200 target cell were
unchaged or tended to increase.
Longer term changes in NK activity measured in
blood samples taken prior to each injection of
rIFN-aA (and - 48 h after the last injection) are
indicated for all patients except No. 12 in Figures 2
and 3. After initiation of treatment (in tests on day
3 or 5), NK activity against the K562 target cell
increased in 9 patients and either decreased (patient
no. 3, 7 and 8) or was essentially unchanged
(patient nos. 14 and 15) (Figures 2a and 2b
respectively.) NK activity returned to pretreatment
or lower levels at day 7 or 9 of treatment and
increases above pretreatment levels were seen only
in patients 1, 4, 7, 8 and 9 after this period. In
contrast NK activity increased in lymphocytes from
10 of the 14 patients against the MM200 target
cells (Figure 3). Exceptions were patients 1, 3, 8
and 11. The increase was most prominent in those
with low pretreatment values and tended to be
more gradual than that noted against the K562
target cell. Increases in NK activity MM200 but
not K562 were seen in studies on patients 4, 5, 6,
14 and 15.
Effects ofrIFN-aeA on IL2 production
IL 2 production by blood lymphocytes taken at
intervals during rIFN-aA administration is shown
in Figure 4. In 12 patients (No. 14 excepted) IL2
production was less in samples taken during the
first week of IFN treatment but recovered to or
above pretreatment levels in the second or
subsequent week or treatment. In 6 patients the
changes in IL2 production after the first week of
treatment tended to parallel the changes in
lymphocyte cytotoxicity against the MM200 target
cell e.g. in studies on patient No. 1, 3, 6, 14 and 15.
IL 2 production did not correlate with changes in
the T4 or T8 T cell populations.822 P. HERSEY et al.
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Figure 4 Sequential changes in IL 2 production from
mitogen (PHA) stimulated PBL during treatment with
rIFN-aA. In practically all patients there was an initial
decrease in IL 2 production at 3rd day of treatment
followed by a return to or above pretreatment levels.
Mean + 1 s.d. of IL2 production from 19 normal
concurrent controls was 9.97 +2.94 units.
Discussion
The response rate of melanoma to treatment by
rIFN-aA in this study consisted of two complete
remissions and stabilization of disease in two
patients. One patient undergoing complete
remission had a solitary pulmonary nodule and the
other both pulmonary and s.c. nodules. Previous
studies have also reported that responses to IFN-a
were confined to metastases in skin (Retsas et al.,
1983) or to skin and pulmonary regions (Creagan et
al., 1984a,b; Pouillart et al., 1984). It was noticeable
that responses were confined to patients with a
good performance status and there were no
responses in those with restricted physical activity
due to their disease. This contrasted with the study
of Creagan et al., (1984b) who observed responses in
both good and poor risk patients. Only one patient
with extensive disease showed any response. This
was a patient with extensive hepatic metastases
which remained stable during treatment for a
period of 8 months.
Evaluation of the patient with a bony metastases
in the neck of the femur was difficult in that there
appeared to be disease progression upon X-ray but
there was no evidence of melanoma in scrapings
obtained at operation for pin and plate of the
hip. There was no evidence of tumour growth at
this site over approximately a year so that this
patient may have had a partial or complete
response at this site. If this patient is included in the
evaluation and the patient who only had 2 weeks of
treatment is excluded the complete response rate
was 3/19 patients or 16% (95% confidence levels
3.4-39.6%). If the patient is considered as
unevaluable the complete response rate was 2/18 or
11% (95% confidence levels 1.4-34.77%). Median
survival for all study participants from the
beginning of treatment was 26 weeks by Kaplan-
Meier life table analysis (Patient numbers are
considered insufficient to make comparisons with
published survivals of disseminated melanoma
which is -6 months overall (Balch et al., 1985).
As reported in other studies (Quesada &
Gutterman, 1983) rIFN-axA administration was
accompanied by a number of side effects which were
severe enough to require dosage reduction from the
50Mum-2 dose in 11 of the 15 patients (see
Appendix 1). This was usually from fatigue or a
combination of fatigue and nausea. Severe hair loss
was noticed in one patient after six months of
treatment and grade three liver toxicity (Miller et
al., 1981) was detected in two patients. Most
patients were able to tolerate the 30Mum-2 dose
and this dose level or less would appear more
realistic in future studies.
One of the objectives of the present study was to
monitor effects of rIFN-xA on several haemato-
logical and immunological tests. Short term (6h)
effects on leukocyte populations consisted of a
marked decrease in lymphocytes and an increase in
neutrophils so that the total leukocyte numbers
tended to remain unchanged. After the 50Mum-2
dose neutrophils did not increase, resulting in a
decrease in total leukocyte numbers. The drop in
lymphocyte numbers appeared to result from a
reduction in T cells giving a relative increase in B
cells. Lymphocyte numbers had returned towards
pretreatment levels by two days prior to the next
rIFN-axA injection so that the changes noted at 6h
may have reflected sequestration of T cells from the
circulation into sites such as the bone marrow. This
is reported to occur after steroid administration
(Haynes & Fauci, 1978) and in these patients may
have resulted from endogenous steroid production
as part of a stress response. The latter may also
explain the marked reduction of NK activity in the
circulation at 6h as steroids are known to produce
this effect (Clarke et al., 1977; Holbrook et al.,
1983). Short term reduction in NK activity after
rIFN-axA was also noted in previous studies
(Lotzova et al., 1983).EFFECTS OF rIFN-aA IN MELANOMA PATIENTS 823
These short term effects on leukocyte populations
appeared to be superimposed on a general
depression of leukocyte numbers (particularly of
neutrophils) and of platelets measured in blood
samples taken before the next dose of rIFN-aA. The
reduction in lymphocyte numbers was not marked
and appeared to affect both B and T cells. The
relative sparing of lymphocyte numbers in the
blood was also noted in previous studies (Golub et
al., 1982) and may indicate selective effects of rIFN-
aA on various progenitor cells in the marrow as
reported elsewhere (Broxymeyer et al., 1983). Within
the T cell population there appeared to be a relative
decrease in the T8 population, particularly when
total lymphocyte numbers were reduced so that the
T4/T8 ratio tended to increase. These changes are
similar to those reported by Silver et al. (1983)
using lymphoblastoid IFN and many reflect growth
inhibitory effects of rIFN-a%A on T cell regeneration
particularly if the T8 population has a higher
turnover rate than the T4 population.
Short term changes in NK activity measured at
6h referred to above, appeared to be superimposed
on longer term changes detected in blood samples
taken 2 days after rIFN-aA administration. These
were characterised, in general, by an increase
against both target cells in the first week of
administration. NK activity against the K562 target
cells then declined to approximate pretreatment
levels as described in previous studies using crude
leukocyte interferon preparations (Golub et al.,
1982). As also noted in previous studies (Lotzova et
al., 1983) the increase in NK activity was more
marked in patients with low pretreatment values.
Although the cytotoxic activity of blood
lymphocytes against the two target cells was similar
in the first week subsequent rIFN-axA treatment was
associated (in 6 patients) with a gradual increase
against the MM200 but not the K562 target cell.
The latter changes did not correlate with changes in
the T4 or T8 populations but did appear to
correlate with IL 2 production from mitogen
stimulated lymphocytes.
These observations may indicate that the
cytotoxic activity against the melanoma cell was
due to lymphokine activated killer (LAK) cells. It
was shown previously that the incubation of
lymphocytes in IL 2 may induce cytotoxic activity
against a wide range of target cells including auto-
logous tumour cells (Hersey et al., 1981; Grimm et
al., 1982) and are considered similar to the
"anomalous killer cells" described by Masucci et al.,
(1980).
MM200 target cells are relatively resistant to NK
activity but are sensitive to killing by LAK cells so
that the increase in cytotoxic activity noted against
the MM200 target cell but not the K562 cells may
indicate endogenous production of LAK cells in
response to enhanced IL 2 production. The latter
may have been induced by administration of rIFN-
aA in the previous studies have shown potentiation
of IL 2 production in vitro by IFN (Blomgren &
Einhorn, 1981).
The relevance of the results from the in vitro
studies to the in vivo effects of rIFN-oaA on
melanoma growth is at present uncertain. Although
NK activity against K562 cells was increased in the
first week of treatment this tended to be short lived
in most of the patients. Previous studies have also
raised doubt concerning the significance of NK
activity in control of tumour growth in melanoma
patients (Hersey et al., 1984). In view of this and
previous studies showing that LAK (but not NK)
can kill autologous tumour cells in vitro this (IL2
induced) activity may be more relevant in control of
tumour growth. In agreement with this an increase
in IL 2 production and cytotoxicity against the
MM200 melanoma cells was documented in one of
the patients undergoing a complete remission but
similar changes were also seen in patients not
responding to rIFN-cxA. Perhaps in the latter
patients other factors such as the size of the tumour
burden and release of immunosuppressive factors
from tumours may need to be considered. These
changes were not observed in the patient with
extensive liver metastases who had stabilization of
tumour growth over a period of 8 months. Arrest of
cell division by IFN as reported elsewhere (Creasey
et al., 1980) may have been more important in this
patient. Whether other mechanisms of action were
responsible for the effects, as reported in
experimental studies (Belardelli et al., 1983) is
unknown.
With respect to future studies on rIFN-aA the
response rate and complications observed in this
study would not appear to justify further evaluation
of dose regimes above 30Mum-2. This and other
studies do however indicate the agent is effective
against melanoma particularly in patients with a
good performance status and pulmonary and or
subcutaneous metastases. Further studies are
required to select such patients who may respond to
IFN and to develop optimal treatment regimes. The
present studies suggest that measurement of IL2
production and LAK activity may assist in these
aims.
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